February 2011 Issue
What has emerged from Pharma's tough journey is a newfound appreciation for business performance.
New paradigms are needed if PATs promise is to be realized for biopharma process control.
As mom used to say on my report card: you could do better.
Our annual survey results say youve just about had enough. Will 2011 be the year things turn in your favor?
A crash course in Twitter hashtags and more, so you can follow the action at Pittcon and Interphex.
Theres no good way to deliver bad news, but that doesnt mean it should be hidden or glossed over.
How can you talk your CEO into paying for Quality by Design if you cant even agree on what its core concepts mean?
Two viable techniques exist for better lyo control in commercial processes, says UConns freeze-drying guru.
At Pfizer, the value of models is not in mimicking reality, but in illustrating the interactions between people, equipment, materials, and time.